CRISPR Therapeutics AG (NASDAQ:CRSP ) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET Company Participants Samarth Kulkarni - CEO Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Good morning, everyone. Welcome again to TD Cowen's 45th Annual Healthcare Conference, our first day.
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Explore the exciting world of CRISPR Therapeutics (CRSP 0.69%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
The rise in CRISPR Therapeutics' share price can be attributed to the better-than-expected Q4 results and a rating upgrade by a well-established financial services firm.
On Hump Day, investors piled into CRISPR Therapeutics (CRSP 9.29%) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized healthcare company's latest quarterly earnings report, which was published after market hours Tuesday.
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim SMID Cap Biotech Conference Transcript February 6, 2025 2:00 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay And thank you for joining Guggenheim during our second SMID Cap conference. I am Debjit, one of the therapeutic analysts here, and joining me from CRISPR Therapeutics is CEO, Samarth Kulkarni.
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49, marking a +1.23% move from the previous day.